Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

Annals of Hematology

Volumn 90, Issue 4, 2011, Pages 473-475

  Scholl, Sebastian ^a   Spies Weisshart, Baerbel ^a   Klink, Anne ^a   Muegge, Lars Olof ^a   Fricke, Hans Joerg ^a   Hochhaus, Andreas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTARABINE; GENOMIC DNA; IDARUBICIN; MITOXANTRONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE DOMAIN 1; PROTEIN TYROSINE KINASE DOMAIN 2; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; PYRIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER RECURRENCE; CASE REPORT; CAUSE OF DEATH; CHROMOSOME TRANSLOCATION 9; COLITIS; CYTOGENETICS; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPLASIA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPERLEUKOCYTOSIS; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SEPSIS; SEQUENCE ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; DRUG RESISTANCE; FATALITY; GENETICS; MIDDLE AGED;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PYRIDINES;

EID: 79955942168     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1027-9     Document Type: Letter

References (13)

1. Yokota S, Kiyoi H, Nakao M, Minami S, Kuriyama K, Takeshita A et al (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 11:1605-1609 (Pubitemid 27458595)
2. Kottaridis PD, Gale RE, Frew ME, Harrison G, Wheatley K, Groves MJ et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759
3. Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, Platzbecker U et al (2002) Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335 (Pubitemid 34627197)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
5. Zhang W, Konopleva M, Shi YX, Shih YX, McQueen T, Harris D et al (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100:184-198 (Pubitemid 351480557)
6. von Bubnoff N, Engh RA, Aberg E, Saenger J, Peschel C, Duyster J (2009) FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69:3032-3041
7. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567-6571
8. Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A et al (2009) Sorafenib (Nexavar [registered]) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD acute myeloid leukemia. Leuk Res 33:348-350
9. Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F (2008) Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49:2246-2255
10. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024-2027
11. White DL, Saunders VA, Dang P, Engler J, Zennettino AC, Cambareri AC et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697-704 (Pubitemid 44061372)
12. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258-264
13. La Rosée P, Hochhaus A (2010) Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 17:91-96